News

An annual study commissioned by Quest Diagnostics and Inovalon reveals interesting findings to keep value-based care moving forward.

The conference raised important points about unregulated growth opportunities and new pharmacy arena players.

A Klick Health survey shows there’s opportunities for healthcare innovation and technology to play larger role in patient’s lives.

A new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.

WalletHub released a study comparing 50 states and the District in terms of 15 key metrics, ranging from arrest and overdose rates to opioid prescriptions and meth-lab incidents per capita.

FDA has approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.

HealthPartners aims to improve price information for consumers. Here’s how.

Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.

MCOs are fighting back against rising pharmaceutical costs. Here are the top strategies they are embracing.

Alternatives to opioids programs emerge as viable tools to mitigate the crisis.

AHIP 2017: SummaCare exec shares their best practices for patient care outreach.

Are you making any of these mistakes? Here are the biggest pitfalls healthcare industry leaders say you should avoid.

AHIP 2017 presentation: The spirit of accountable care keeps providers’ focus on data-driven clinical solutions.

Oak Street Health co-founder tells AHIP 2017 attendees about its novel approach to patient care.

AHIP 2017: Kaveh Savafi, MD, of Accenture, tells Managed Healthcare Executive about the biggest digital trends and their impact on healthcare.

A new RAND analysis of retail clinics finds they could be increasing healthcare costs.

Digital health pioneer Eric Topol talks about plans for a four-year precision medicine study at AHIP 2017.

AHIP 2017: Older adults with complex chronic conditions require payers to “look under the hood.”

Lilly's galcanezumab proves successful in three phase 3 migraine studies. Here are the findings.

AstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.

The days of the traditional, channel-focused and largely enshrouded PBM business model have come and gone. Here’s what’s next.

New research shows hypertension, diabetes influence survival of ovarian cancer patients in different ways.

Alcohol consumption is known to be a risk factor for breast cancer based on studies predominantly done in white women. Now, a University of North Carolina Lineberger Comprehensive Cancer Center study has found the same risk exists for black women.

Technology advances in pharmacy include innovations that improve medication safety, efficiency, and patient compliance.

It has been an exciting time at the Myeloma Institute at the University of Arkansas for Medical Sciences, on all fronts, namely, embarking on research that could play an important role in the development of preventative and curative strategies for multiple myeloma in the future.

Value-based drug contracting between manufacturers and payers is picking up steam-appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.

Here are three things to consider when developing a population health management team at your organization.

Key socioeconomic data that will help you care for your most vulnerable populations.

FDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.

A new report reveals how personalized medicine can make patients healthier while lowering costs.